High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis. 2016

Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.

BACKGROUND Epidemiologic evidence suggests that chronic inflammation and/or chronic infection is associated with cancer development, and the inflammatory process may play a crucial role in the carcinogenesis and prognosis of colorectal cancer (CRC). Substance P (SP) belongs to the family of tachykinins and acts as an immunomodulator, binding to the neurokinin-1 receptor (NK1R) to initiate tumor cell proliferation, angiogenesis, and migration, steps that are critical for tumor cell invasion and metastasis. It is suggested that SP/NK1R signaling may play an important role in cancer progression and metastasis. However, the exact involvement and significance of SP and NK1R in CRC pathologies remain to be adequately deciphered. METHODS We performed immunohistochemistry staining on tissue microarrays containing 267 pairs of CRC and adjacent normal tissues to evaluate the clinical significance of SP or NK1R in the progression and prognosis of CRC. We also explored the potential correlation between SP and NK1R in CRC development. RESULTS Expression levels of SP and NK1R were upregulated in CRC compared with their expressions in adjacent normal tissues (P<0.001). High expression of SP in CRC was significantly associated with lymph node metastasis (P<0.001). We also found that high expression of NK1R in CRC was significantly related to TNM (tumor node metastasis) stage (P=0.010) and lymph node metastasis (P=0.019). A high correlation between SP and NK1R expression was also observed (r=0.419, P<0.001). Survival analysis showed that CRC patients with high expression of SP or NK1R have a poor prognosis when compared to patients with low SP or NK1R expression (log rank test, P<0.05). Multivariate analysis using Cox regression model showed that survival was independently correlated with lymph node metastasis, distant metastasis, and SP expression (P<0.05). CONCLUSIONS Upregulation of SP-NK1R may play a crucial role in CRC progression. Moreover, SP-NK1R expression may also be used as a predictor for CRC prognosis.

UI MeSH Term Description Entries

Related Publications

Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
October 2000, The Journal of allergy and clinical immunology,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
August 2006, Journal of surgical oncology,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
January 2009, Histopathology,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
October 2020, Clinical genetics,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
July 2022, Cancers,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
April 2007, European journal of cancer (Oxford, England : 1990),
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
October 2022, Reports of biochemistry & molecular biology,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
January 2017, PloS one,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
April 2015, Oncology reports,
Xiao-Yi Chen, and Guo-Qing Ru, and Ying-Yu Ma, and Jun Xie, and Wan-Yuan Chen, and Hui-Ju Wang, and Shi-Bing Wang, and Li Li, and Ke-Tao Jin, and Xiang-Lei He, and Xiao-Zhou Mou
June 2022, Molecular biology reports,
Copied contents to your clipboard!